Neuralink, founded in 2016 by Elon Musk and a team of scientists and engineers, is a neurotechnology company developing implantable brain-computer interfaces (BCIs). Headquartered in Fremont, California, the company aims to create devices that can treat serious brain diseases in the short term, with the long-term goal of human enhancement and achieving symbiosis with artificial intelligence. Neuralink's flagship product is the N1 Implant, also known as the Link or Telepathy N1, a coin-sized device designed to decode neural signals, enabling users to control digital devices with their thoughts. The company is also working on an experimental device called Blindsight to restore vision in individuals with optic nerve damage by directly stimulating the visual cortex.
Neuralink has raised $1.29 billion in funding over 6 rounds. The latest funding round, a Series E on May 27, 2025, secured $650 million. Investors include Founders Fund and Vy Capital. As of January 31, 2026, Neuralink has 624 employees. Key executives include DJ Seo (Co-Founder, President & COO), and Joseph O'Doherty (Head of Next Gen). Elon Musk leads the company as CEO, driving the strategy with support from experts like Dr. Matthew MacDougall. News on January 1, 2026, Elon Musk announced that Neuralink intends to start high-volume production of its brain-computer interface (BCI) devices by 2026, along with a shift toward fully automated surgical implantation.